305 related articles for article (PubMed ID: 17825459)
21. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R
Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910
[TBL] [Abstract][Full Text] [Related]
22. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
Yang C; Shi H; Zhou J; Liang Y; Xu H
Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
[TBL] [Abstract][Full Text] [Related]
23. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
Bakker WA; Thomassen YE; van't Oever AG; Westdijk J; van Oijen MG; Sundermann LC; van't Veld P; Sleeman E; van Nimwegen FW; Hamidi A; Kersten GF; van den Heuvel N; Hendriks JT; van der Pol LA
Vaccine; 2011 Sep; 29(41):7188-96. PubMed ID: 21651934
[TBL] [Abstract][Full Text] [Related]
24. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial.
Liao G; Li R; Li C; Sun M; Li Y; Chu J; Jiang S; Li Q
J Infect Dis; 2012 Jan; 205(2):237-43. PubMed ID: 22158682
[TBL] [Abstract][Full Text] [Related]
25. Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines.
Westdijk J; Brugmans D; Martin J; van't Oever A; Bakker WA; Levels L; Kersten G
Vaccine; 2011 Apr; 29(18):3390-7. PubMed ID: 21397718
[TBL] [Abstract][Full Text] [Related]
26. Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan.
Horie H; Yoshida H; Matsuura K; Miyazawa M; Wakabayashi K; Nomoto A; Hashizume S
J Med Virol; 2002 Nov; 68(3):445-51. PubMed ID: 12226835
[TBL] [Abstract][Full Text] [Related]
27. Repertoire of antibodies against type 1 poliovirus in human sera.
Rezapkin G; Neverov A; Cherkasova E; Vidor E; Sarafanov A; Kouiavskaia D; Dragunsky E; Chumakov K
J Virol Methods; 2010 Nov; 169(2):322-31. PubMed ID: 20691212
[TBL] [Abstract][Full Text] [Related]
28. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants.
Asturias EJ; Dueger EL; Omer SB; Melville A; Nates SV; Laassri M; Chumakov K; Halsey NA
J Infect Dis; 2007 Sep; 196(5):692-8. PubMed ID: 17674310
[TBL] [Abstract][Full Text] [Related]
29. A novel gamma radiation-inactivated sabin-based polio vaccine.
Tobin GJ; Tobin JK; Gaidamakova EK; Wiggins TJ; Bushnell RV; Lee WM; Matrosova VY; Dollery SJ; Meeks HN; Kouiavskaia D; Chumakov K; Daly MJ
PLoS One; 2020; 15(1):e0228006. PubMed ID: 31999745
[TBL] [Abstract][Full Text] [Related]
30. Antigenic analysis of poliovirus type 3 using monoclonal antibodies.
Ferguson M; Minor PD; Magrath DI; Schild GC
Dev Biol Stand; 1984; 57():151-5. PubMed ID: 6098495
[TBL] [Abstract][Full Text] [Related]
31. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus.
Tiwari M; Parida M; Santhosh SR; Khan M; Dash PK; Rao PV
Vaccine; 2009 Apr; 27(18):2513-22. PubMed ID: 19368794
[TBL] [Abstract][Full Text] [Related]
32. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
[TBL] [Abstract][Full Text] [Related]
33. [A monoclonal antibody panel for the intratypic differentiation of type-2 polioviruses].
Shyrobokov VP; Nikolaienko IV; Kopanytsia LV; Solohub VK; Ivanova OIe
Mikrobiol Z; 1997; 59(6):27-36. PubMed ID: 9511373
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age.
Ong-Lim AL; Shukarev G; Trinidad-Aseron M; Caparas-Yu D; Greijer A; Duchene M; Scheper G; van Paassen V; Le Gars M; Cahill CP; Schuitemaker H; Douoguih M; Jacquet JM
Hum Vaccin Immunother; 2022 Nov; 18(5):2044255. PubMed ID: 35344464
[TBL] [Abstract][Full Text] [Related]
35. Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats.
Ma L; Cai W; Sun M; Cun Y; Zhou J; Liu J; Hu W; Zhang X; Song S; Jiang S; Liao G
Hum Vaccin Immunother; 2016 Dec; 12(12):3125-3131. PubMed ID: 27558963
[TBL] [Abstract][Full Text] [Related]
36. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains.
Verdijk P; Rots NY; Bakker WA
Expert Rev Vaccines; 2011 May; 10(5):635-44. PubMed ID: 21604984
[TBL] [Abstract][Full Text] [Related]
37. [Application of ELISA for screening McAb against type III polioviruses and its antigenic analysis].
Gu FZ; Wang SH; Sun YY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1985 Oct; 7(5):359-63. PubMed ID: 2421926
[No Abstract] [Full Text] [Related]
38. Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccines.
Kouiavskaia D; Puligedda RD; Dessain SK; Chumakov K
J Virol Methods; 2020 Feb; 276():113785. PubMed ID: 31765719
[TBL] [Abstract][Full Text] [Related]
39. Genetic stability of Sabin 1 strain of poliovirus: implications for quality control of oral poliovirus vaccine.
Rezapkin GV; Alexander W; Dragunsky E; Parker M; Pomeroy K; Asher DM; Chumakov KM
Virology; 1998 Jun; 245(2):183-7. PubMed ID: 9636357
[TBL] [Abstract][Full Text] [Related]
40. Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats.
Murakami K; Fujii Y; Someya Y
Vaccine; 2020 Apr; 38(17):3295-3299. PubMed ID: 32197923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
